GlassScriptPhysician profile
Gary Robert Pineless
NPI 1700806858
$9,151.59
in general payments reported to CMS, 2019-2025
28 companies · $2,261 in 2025
The $2,261 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $324 · 2021: $895 · 2022: $1,131 · 2023: $1,504 · 2024: $2,430 · 2025: $2,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,195.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,118.83 | 2019-2025 | Farxiga, Wainua, Brilinta |
| Novartis Pharmaceuticals Corporation | $1,075.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,065.74 | 2019-2025 | Opsumit, Uptravi, Xarelto |
| Novo Nordisk INC | $1,062.29 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,002.91 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $683.08 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $462.65 | 2019-2025 | Repatha |
| Abbott Laboratories | $395.04 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $368.81 | 2020-2025 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $318.02 | 2019-2025 | |
| Medtronic, INC. | $311.61 | 2021-2025 | Linq II, Selectsecure, Corevalve Evolut R |
| Abiomed | $207.56 | 2023-2025 | Impella |
| Edwards Lifesciences Corporation | $161.65 | 2022 | |
| Merck Sharp & Dohme LLC | $160.37 | 2023-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $127.28 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $102.69 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $94.23 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $71.53 | 2025 | |
| Alnylam Pharmaceuticals INC. | $71.52 | 2025 | Onpattro |
| Scpharmaceuticals INC. | $59.11 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $54.96 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $42.62 | 2022-2025 | Nexletol |
| Lilly USA, LLC | $34.90 | 2024 | Zepbound, Jardiance |
| Davol INC. | $25.85 | 2025 | Progel Applicator Spray Tips |
| Ionis Pharmaceuticals, INC. | $23.77 | 2025 | Tryngolza |
| Medtronic Vascular, INC. | $22.60 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $16.65 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Pineless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.